Extended Data Fig. 8: Survival outcomes by detectable vs. undetectable ctDNA status at baseline.
From: ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
(a) Patients with undetectable ctDNA at baseline (n = 10) had numerically longer PFS compared to patients with detectable ctDNA (n = 35, median PFS 8.31 vs 2.96 months). (b) Similar trends were noted for overall survival, such that patients with detectable ctDNA at baseline (n = 10) had numerically shorter OS compared to individuals with undetectable ctDNA at baseline (n = 35, median OS 10.94 vs. 16.89 months).
